101 related articles for article (PubMed ID: 6399617)
1. Cytotoxic agents in prostate cancer: an enigma.
Yagoda A
Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617
[No Abstract] [Full Text] [Related]
2. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate].
Nogueira March JL; Ojea A; Jamardo D; Díez E; Figueiredo L
Arch Esp Urol; 1985; 38(1):28-34. PubMed ID: 4039554
[No Abstract] [Full Text] [Related]
3. Cooperative clinical trials in prostate cancer.
Murphy GP; Slack NH
Prog Clin Biol Res; 1981; 75B():341-6. PubMed ID: 7323102
[No Abstract] [Full Text] [Related]
4. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
Sartor O
J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
[No Abstract] [Full Text] [Related]
5. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
Németh A; Morvay J; Vécsei B
Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
[No Abstract] [Full Text] [Related]
6. Carcinoembryonic antigen as an adjunct to determination of clinical stage in prostate cancer.
Kane RD; Paulson DF
Natl Cancer Inst Monogr; 1978 Dec; (49):231. PubMed ID: 748775
[TBL] [Abstract][Full Text] [Related]
7. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
Müntzing J; Shukla SK; Chu TM; Mittelman A; Murphy GP
Invest Urol; 1974 Jul; 12(1):65-8. PubMed ID: 4835492
[No Abstract] [Full Text] [Related]
9. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy.
Jayaprakash S; Wang X; Heston WD; Kozikowski AP
ChemMedChem; 2006 Mar; 1(3):299-302. PubMed ID: 16892363
[No Abstract] [Full Text] [Related]
10. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.
Moore MR; Troner MB; DeSimone P; Birch R; Irwin L
Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053
[No Abstract] [Full Text] [Related]
12. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
13. Biologic and pathophysiologic prognosticating indices in prostatic cancer.
Madduri SD; Sporer A; Seebode JJ
Am Surg; 1978 May; 44(5):290-5. PubMed ID: 666117
[No Abstract] [Full Text] [Related]
14. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
15. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Tiffany NM; Wersinger EM; Garzotto M; Beer TM
Urology; 2004 May; 63(5):934-9. PubMed ID: 15134984
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced prostate cancer: 25 years later.
Logothetis CJ; Millikan R
J Clin Oncol; 2008 May; 26(15):2423-4. PubMed ID: 18487561
[No Abstract] [Full Text] [Related]
18. Chemotherapy in advanced prostate cancer.
Beedassy A; Cardi G
Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
[TBL] [Abstract][Full Text] [Related]
19. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
Miglietta L; Cannobbio L; Boccardo F
Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
Kelloff GJ; Coffey DS; Chabner BA; Dicker AP; Guyton KZ; Nisen PD; Soule HR; D'Amico AV
Clin Cancer Res; 2004 Jun; 10(11):3927-33. PubMed ID: 15173102
[No Abstract] [Full Text] [Related]
[Next] [New Search]
